Intravenous PRGN-3005 Plus Lymphodepletion Shows Early Promise in Ovarian Cancer
PRGN-3005 autologous UltraCAR T cells given with or without lymphodepletion was well tolerated and reduced overall tumor burden in heavily pretreated patients with ovarian cancer, according to data from a phase 1/1b study (NCT03907527).
Results presented at the 2023 ASCO Annual Meeting showed that intravenous administration of the product resulted in dose-dependent T-cell expansion regardless of subsequent lymphodepletion. However, the addition of lymphodepletion stabilized or decreased CA125 levels in 89% of patients (n = 9).
Notably, patients who received the single intravenous infusion of PRGN-3005 after lymphodepletion experienced a 67% reduction in tumor burden, and administration of 2 infusions in a patient led to a 28% reduction in tumor burden. PRGN-3005 was well tolerated and did not produce any dose-limiting toxicities, neurotoxicity, or ophthalmologic adverse effects (AEs).
“With the cytokine added to the CAR T-cell construct, we will potentially overcome some of the major barriers that [exist with] getting this type of approach to work in patients with solid tumors,” Disis said in an interview with OncLive.
ارسال به دوستان